加速中等收入国家免疫规划进展的机遇
文章指出中等收入国家(尤其非Gavi资格或已 transition 出Gavi支持的国家)免疫规划面临疫苗获取挑战,COVID-19大流行加剧了项目挑战、延迟引入、覆盖下滑和不公平。文章呼吁利用Gavi 5.0、免疫议程2030及区域机制等机遇,通过多利益相关方协商确定的行动领域加速进展。
要点
- 中等收入国家免疫系统在COVID-19下更脆弱,面临疫苗引入延迟、覆盖下滑和不公平加剧风险。
- 建模估计2020年引入肺炎球菌结合疫苗、轮状病毒疫苗和HPV疫苗并达90%覆盖可挽救约7万生命。
核心结论
- 中等收入国家免疫改善的健康和公平影响巨大,应利用Gavi 5.0、免疫议程2030及区域机制等机遇,将多利益相关方协商确定的行动领域付诸实施,并适应具体国家情境。
研究设计与样本
- 本文为针对中等收入国家免疫规划进展的政策性综述与多利益相关方协商总结,未报告系统检索范围或原始研究样本量。
主要发现
- 建模提示,2020年在这组Gavi过渡和非Gavi资格中等收入国家引入肺炎球菌结合疫苗、轮状病毒疫苗和HPV疫苗,若达90%覆盖,可挽救约7万生命。
关键数值与推荐
- 2015年SAGE认可的共享伙伴中等收入国家战略记录了利益相关方识别免疫挑战的努力。
- Gavi 5.0和免疫议程2030提供对齐中等收入国家战略和协调全球支持的机会。
临床怎么用
- 利益相关方应共同将本文强调的发现付诸行动,适应具体国家情境,并从现有努力中学习并加以建设。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There has been increasing recognition of vaccine access challenges in middle-income countries and the need for increased action, particularly in countries that are not eligible for or have transitioned out of Gavi, the Vaccine Alliance support. These countries' immunization systems are more vulnerable than ever as the COVID-19 pandemic exacerbates existing programme challenges, increasing the risk of delayed vaccine introductions, backsliding immunization coverage rates, and increased coverage inequity. The potential health and equity impact of improving immunization outcomes in middle-income countries is substantial. Modelling suggests that the introduction of pneumococcal conjugate vaccine and vaccines for rotavirus and human papillomavirus in this set of Gavi-transitioned and non-Gavieligible middle-income countries in 2020 could have saved an estimated 70,000 lives if 90 % coverage had been reached. Further, increasing coverage for already-introduced vaccines to 90 % could have saved an additional estimated 16,000 lives. Over the past decade, stakeholders have made considerable efforts to identify immunization challenges in middle-income countries as documented in the 2015 SAGE-endorsed Shared Partner Middle-Income Country Strategy. In the coming decade, new global platforms like Gavi 5.0 and the Immunization Agenda 2030 provide opportunities to align on MIC strategies and provide coordinated global support to middle-income countries. The international COVID-19 pandemic response has the potential to lay the foundation for long term support beyond the scope of COVID-19 to non-Gavi eligible middle-income countries. Meanwhile regional mechanisms to address immunization barriers in middle-income countries have grown in number and strength, offering sustainable platforms for cross-country collaboration and the provision of tailored technical support. To ensure that these opportunities are successfully acted upon and that middle-income countries achieve the Immunization Agenda 2030 goals, comprehensive, multi-stakeholder consultations were conducted to identify areas of action with the greatest potential to accelerate immunization progress. Stakeholders should work together to put these findings, highlighted in this paper, into action, adapting their approaches to specific country contexts and learning from and building on existing efforts.
引用
- Zhu J, Cole CB, Fihman J, et al. Opportunities to accelerate immunization progress in middle-income countries. Vaccine. 2023. PMID: 37460357. doi:10.1016/j.vaccine.2023.06.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。